SEC Tracker
Get the app

Naploy NPLY

Naploy Q1 FY26: revenue $4K, up 525%; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Naploy reported for Q1 FY26, the quarter ended Oct 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$4K+525% from $581 in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$7KAgainst −$10K in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS$0.00Against $0.00 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$10K−64% from $28K in Q1 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$3KAgainst −$6K in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Naploy files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8000 and related industry codes: the same peer list as the financial tables.

  1. Alps Group ALPS
  2. American Oncology Network AONC
  3. Agape ATP ATPC public float $5M, Dec 31, 2025
  4. Anew Health AVG
  5. Better Therapeutics BTTX